3,3,3-trifluoro-1-(4-(trifluoromethyl)phenyl)propan-1-ol | 1272903-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3,3-trifluoro-1-(4-(trifluoromethyl)phenyl)propan-1-ol
• 英文别名: 3,3,3-Trifluoro-1-[4-(trifluoromethyl)phenyl]propan-1-ol
• CAS: 1272903-05-5
• 化学式: C₁₀H₈F₆O
• mdl: MFCD17390117
• 分子量: 258.163
• InChiKey: WOKWUAABKUBKNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3,3,3-trifluoro-1-(4-(trifluoromethyl)phenyl)propan-1-one 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 3,3,3-trifluoro-1-(4-(trifluoromethyl)phenyl)propan-1-ol
  参考文献：
  名称：

  [EN] DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  [FR] COMPOSÉS DIHYDROPYRAZOLOPYRIMIDINONE UTILISÉS EN TANT QU'EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及式(I)的二氢吡唑并嘧啶酮化合物，该化合物作为治疗与磷酸二酯酶2 (PDE2)相关的中枢神经系统障碍的治疗剂是有用的。本发明还涉及使用这些化合物来治疗神经和精神障碍，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。

  公开号：

  WO2016192083A1

文献信息

• Sunlight-driven trifluoromethylation of olefinic substrates by photoredox catalysis: A green organic process
  作者：Munetaka Akita、Takashi Koike

  DOI：10.1016/j.crci.2015.01.013

  日期：2015.7

  types of catalytic photoredox processes following the reductive quenching cycle (RQC) and the oxidative quenching cycle (OQC), the discussion is focused on organic transformations based on OQC, in particular the trifluoromethylation of olefinic substrates with electrophilic trifluoromethylating reagents furnishing solvolytic addition products and substitution products. It is concluded that catalytic

  摘要 描述了光氧化还原催化在有机合成中的原理和应用。在简要描述了还原淬灭循环 (RQC) 和氧化淬灭循环 (OQC) 之后的两种催化光氧化还原过程的特征后，讨论的重点是基于 OQC 的有机转化，特别是烯烃底物的三氟甲基化与亲电三氟甲基化试剂一起提供溶剂分解加成产物和取代产物。得出的结论是，从危害性、安全性和能源（可见光，包括阳光）的角度来看，催化光氧化还原系统是绿色的。还将讨论光氧化还原催化的未来前景。
• Cobalt–Tertiary-Amine-Mediated Hydroxytrifluoromethylation of Alkenes with CF₃Br and Atmospheric Oxygen
  作者：Qiankun Li、Wu Fan、Deqian Peng、Bingyin Meng、Shaohan Wang、Rui Huang、Shihao Liu、Suhua Li

  DOI：10.1021/acscatal.0c00498

  日期：2020.4.3

  The mild and efficient hydroxytrifluoromethylation of alkenes with bromotrifluoromethane (CF3Br) and atmospheric oxygen mediated by cobalt-tertiary amine is described. This reaction proceeds with broad substrate scope and good functional group compatibility. Mechanistic studies indicate that the reaction proceeds through a radical pathway, which is enabled by combination of the previously unexplored

  描述了由溴三氟甲烷（CF 3 Br）和钴叔胺介导的大气氧对烯烃进行的温和有效的羟基三氟甲基化反应。该反应在广泛的底物范围和良好的官能团相容性下进行。机理研究表明，反应是通过自由基途径进行的，这是通过将先前未开发的高效N-异丙基-N，2-二甲基丙烷-2-胺与Co（II）结合使用来实现CF 3 Br的单电子还原CF 3自由基。
• Three-component Oxytrifluoromethylation of Alkenes: Highly Efficient and Regioselective Difunctionalization of CC Bonds Mediated by Photoredox Catalysts
  作者：Yusuke Yasu、Takashi Koike、Munetaka Akita

  DOI：10.1002/anie.201205071

  日期：2012.9.17

  Here comes the sun: A facile vicinal difunctionalization of alkenes, oxytrifluoromethylation, was established by visible‐light‐driven photoredox catalysis. Judicious choice of the CF3 source is key. Nucleophiles such as water, alcohols, and carboxylic acids can be used in this highly efficient (2–4 h) and regioselective (100 %) transformation using light‐emitting diode (LED) lamps and natural sunlight

  太阳来了：通过可见光驱动的光氧化还原催化建立了烯烃的邻位双官能化，即氧三氟甲基化。明智地选择CF 3信号源是关键。可以使用发光二极管（LED）灯和自然阳光在这种高效（2-4h）和区域选择性（100％）转化中使用亲核试剂，例如水，醇和羧酸。SET =单电子转移。
• 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10160762B2

  公开（公告）日：2018-12-25

  The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

  本发明涉及式（I）的6-烷基二氢吡唑嘧啶酮化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10174037B2

  公开（公告）日：2019-01-08

  The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式（I）的二氢吡唑嘧啶酮化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底节功能障碍相关的疾病。